Paul Grint has been appointed CEO of AmpliPhi Biosciences (NYSE MKT: APHB). He replaces Scott Salka, who has resigned his CEO and director positions at the San Diego company. No reason was given for Salka’s resignation but AmpliPhi said that he would be a consultant to the company as Grint takes on his new role.
Grint has served on AmpliPhi’s board of directors since 2015 and his experience includes executive posts at drug developers such as Regulus Therapeutics (NASDAQ: RGLS) and Cerexa Pharmaceuticals. AmpliPhi is a decades-old company that began as Seattle-based gene therapy biotech Targeted Genetics. In 2011, the company pivoted to developing bacteriophages as treatments for bacterial infections. AmpliPhi is currently in a Phase 1 clinical trial testing a phage that treats multi-drug resistant bacterial infections.